1. |
Do 90-minute TIMI grade flows predict mortality in acute MI? |
|
Inpharma Weekly,
Volume &NA;,
Issue 1152,
1998,
Page 2-2
&NA;,
Preview
|
PDF (840KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
2. |
The promise of vaccines and gene therapy in skin disease |
|
Inpharma Weekly,
Volume &NA;,
Issue 1152,
1998,
Page 3-4
Peter Harrigan,
Preview
|
PDF (1523KB)
|
|
摘要:
The development of vaccines and gene therapy for skin diseases is gathering pace. Of the 2 approaches, vaccine therapy may be inching ahead at the moment, since there are still as many questions as there are answers to clinical problems associated with applying gene therapy theory. Several vaccines are currently either in clinical trials or under late-stage development, but their effectiveness is still unknown. In discussing both approaches, speakers at the Clinical Dermatology 2000 meeting [Singapore; June 1998] highlighted current vaccines against melanoma and one speaker described the rationale for gene therapy as a generic answer to the treatment of DNA-based disease, whether due to gene or somatic mutations, as ‘overwhelmingly compelling’.
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
3. |
Pharmacotherapy recommendations for panic disorder |
|
Inpharma Weekly,
Volume &NA;,
Issue 1152,
1998,
Page 4-4
&NA;,
Preview
|
PDF (744KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
4. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1152,
1998,
Page 5-5
&NA;,
Preview
|
PDF (846KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
5. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1152,
1998,
Page 6-6
&NA;,
Preview
|
PDF (763KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
6. |
DT388-GM-CSFpotential for resistant and sensitive AML |
|
Inpharma Weekly,
Volume &NA;,
Issue 1152,
1998,
Page 7-7
&NA;,
Preview
|
PDF (672KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
7. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1152,
1998,
Page 8-8
&NA;,
Preview
|
PDF (751KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
8. |
Abarelix ablates testosterone production in prostate cancer |
|
Inpharma Weekly,
Volume &NA;,
Issue 1152,
1998,
Page 9-10
Andrew Bowser,
Preview
|
PDF (1557KB)
|
|
摘要:
Hormonal therapy for prostate cancer, once used primarily to reduce the circulating level of male hormones in patients with advanced disease, is being used more frequently as a synergistic adjunct to radiotherapy or radical surgery. The advent of agonist-induced reduction in testosterone levels represented an improvement in treatment over both bilateral orchiectomy and the use of female hormones, which have a broad spectrum of cardiovascular complications in men with prostate cancer. An even more desirable method of androgen blockade is using an antagonist which blocks gonadotrophin-releasing hormone (GnRH) receptors. This causes an immediate and complete reduction of testosterone production to the level of medical castration - the goal of ablation therapy in men with prostate cancer. Recent data on one such agent, abarelix, which is about to enter phase III clinical trials, were presented at the 80th Annual Meeting of The Endocrine Society [New Orleans, US; June 1998].
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
9. |
Melanotan-II may have potential in erectile dysfunction |
|
Inpharma Weekly,
Volume &NA;,
Issue 1152,
1998,
Page 10-10
&NA;,
Preview
|
PDF (789KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|
10. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1152,
1998,
Page 11-11
&NA;,
Preview
|
PDF (716KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1998
数据来源: ADIS
|